Status:
TERMINATED
Adherence to Antidepressant Treatment in Subjects With Depression
Lead Sponsor:
Laureate Institute for Brain Research, Inc.
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study aims to determine whether a combination a first-line antidepressant plus "RT2CK17" in a capsule relative to a first-line antidepressant plus placebo in a capsule results in higher rates of ...
Eligibility Criteria
Inclusion
- Baseline QIDS-SR ≥ 14 (moderate depression)
- Age 18 - 65
- Written Informed Consent
- Major Depressive Disorder, single-episode/recurrent, not in remission
Exclusion
- RT2CK17-related exclusions
- Uncontrolled hyperthyroidism
- Glaucoma
- Motor tics
- Monoamine oxidase inhibitor treatment
- Serious coronary artery disease, cardiomyopathy, serious cardiac arrhythmias
- Uncontrolled hypertension
- Peripheral vasculopathy
- Pregnancy
- Bipolar Disorder
- Psychotic Disorder
- History of intolerability of study medications
- Currently taking psychiatric medications
- Current Substance Use Disorder (other than nicotine)
- Current Alcohol Use Disorder
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2019
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT03388164
Start Date
January 1 2018
End Date
May 15 2019
Last Update
September 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laureate Institute for Brain Research
Tulsa, Oklahoma, United States, 74136